Moderna receives full FDA approval: is it time to buy the stock?
- Sanctuary Wealth's CIO Jeff Kilburg says buy Moderna Inc on sale.
- Stephen Weiss also added to his position in MRNA on Monday
- Shares of the biotech firm are down 65% from their recent high.
Moderna Inc (NASDAQ: MRNA) is now in the “oversold” territory after a 65% hit to its stock price over the past six months, says Sanctuary Wealth’s chief investment officer.
Why Kilburg likes Moderna
On CNBC’s “Power Lunch”, Jeff Kilburg said he was interested in owning Moderna on sale as the company had promising prospects for future growth.
Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today.
I want to be a buyer here. Moderna has become a household name; it’s a high beta biotech stock that went up over 400% in 2020, nearly 150% in 2021, so it makes sense that it’s consolidating; seeing tremendous profit-taking. We see opportunity in this $65 billion biotech company.
Moderna received full FDA approval for its COVID-19 vaccine on Monday. Spikevax is now the only shot, other than Pfizer’s Comirnaty that has full backing from the regulator. The biotech company also launched a clinical trial for its omicron-specific vaccine last week.
Weiss is also bullish on MRNA
Kilburg’s outlook is similar to Stephen Weiss, who added to his position in MRNA on Monday. In a separate interview on CNBC’s “Halftime Report”, the founder of Short Hills Capital Partners said:
Fundamentals have gotten better. It’s so much more than a COVID company. The pipeline’s grown over the last year from 23 to over 40. They have $15 billion in cash. They’ve already sold 18.5 billion in vaccine for 2022, with option for governments and institutions to take another 3.5 billion.
Weiss also reminded that the sell-off was not specific to Moderna. The biotech space at large has been in a freefall since August 2021. The Massachusetts’ based company is set to report its Q4 results in the last week of February. MRNA trades at a PE multiple of 10.28.